Dr. Kenneth I. Maynard is a Global Program Leader in the CNS Therapeutic Area Unit at Takeda Pharmaceuticals, Inc., responsible for leading multifunctional teams in the clinical development of drugs to treat diseases of the central nervous system.
He was formerly Global Head of External Innovation in the Therapeutic Strategic Unit, Aging at Sanofi (2010-2014). Prior to this position, he spent 5 years as a Project Director (2005-2009) responsible for leading multifunctional teams in the clinical development of central nervous system (CNS) compounds and 5 years in CNS drug discovery research as Principal Scientist and Section Head for Cerebrovascular Disorders (2000–2004) at Sanofi-Aventis (formerly Aventis Pharmaceuticals, Inc.).
Prior to joining the pharmaceutical industry, Dr. Maynard was Assistant Professor in Surgery (Neurosurgery) at Harvard Medical School and Assistant Neuroscientist in the Neurosurgical Service, at Massachusetts General Hospital.
Dr. Maynard holds B.Sc., (Human Sciences with Neuroscience) M.Sc. (Neurological Science) and Ph.D (Neurobiology) degrees from University College, London, U.K. He serves in leadership roles as an elected Fellow of the American Heart Association (F.A.H.A.) and the Society for Neuroscience. He also serves on the Executive Committee of the International Dose-Response Society.
He has authored more than 45 scientific publications and serves on the editorial committees of Current Neurobiology, Recent Patent Reviews on CNS Drug Discovery and ISRN Vascular Medicine.